Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments - and wildly different outcomes for patients as a result.
By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumours, researchers from the University of Michigan Rogel Cancer Center have identified the cells from which different subtypes originate, the pathways involved and how the tumour microenvironment impacts cancer development and response to treatment.
The findings, published in PNAS, could help researchers better understand what forces are influencing renal cell carcinoma and guide oncologists in selecting the best treatment for each patient.
"Single cell RNA sequencing was key to allowing us to monitor gene expression patterns in each individual cell, revealing the mechanisms at play within the tumour microenvironment that can predict overall survival," says study author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at Michigan Medicine.
Researchers generated gene expression atlases of both normal kidney and renal cell carcinoma samples.
They predicted the putative cell of origin for more than 10 subtypes of renal cell cancer.
The analysis also revealed pathways and interactions within the tumour microenvironment that predicted whether the tumour would respond to immunotherapy.
This could lead to biomarkers to help guide kidney cancer treatment.
"By understanding the cell type where a cancer originates, it may allow us to target more precise treatments for that cancer type as well as better understand response to therapy," Chinnaiyan says.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.